## **Complete listing of claims:**

- (previously presented) A pharmaceutical dosage form comprising (a) at least
  one agent effective in treatment of sexual dysfunction having a molecular
  weight, excluding counterions, not greater than 250, in a therapeutically or
  sexual-stimulatorily
  effective total amount, and (b) at least one pharmaceutically acceptable
  excipient; the dosage form being an oral dosage form selected from the
  group consisting of fast-melt formulations, breath-freshening pastilles,
  chewing gums, sublingual tablets, mucoadhesive films and oral strips,
  and having acceptable organoleptic properties.
- 2. (original) The dosage form of Claim 1 wherein the at least one agent has a molecular weight, excluding counterions, not greater than 235.
- 3. (original) The dosage form of Claim 1 wherein the at least one agent has a molecular weight, excluding counterions, not greater than 220.
- 4. (original) The dosage form of Claim 1 wherein the at least one agent has a solubility in water at 20-25°C of at least about 10 g/l.
- 5. (original) The dosage form of Claim 1 wherein the at least one agent is a compound having the formula

wherein X is 0 or S; or a pharmaceutically acceptable salt thereof.

- 6. (original) The dosage form of Claim 1 wherein the total amount of the at least one agent per dose is lower than an amount causing significant side-effects.
- 7. (original) The dosage form of Claim 1 wherein the therapeutic agent is sumanirole or a salt thereof and is present in an amount of about 0.05 mg to about 5

-4-

mg per dose.

- 8. (original) The dosage form of Claim I wherein the therapeutic agent is (R)-5,6-dihydro-5(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione or a salt thereof and is present in an amount of about 0.05 mg to about 5 mg per dose.
- 9. (original) The dosage form of Claim 8 wherein the therapeutic agent is present in an amount of about 0.1 to about 3 mg per dose.

10-15. (cancelled)

- 16. (previously presented) The dosage form of Claim 1 that dissolves in the mouth without need for drinking water or other fluid.
- 17. (previously presented) The dosage form of Claim 1 that is a breath-freshening pastille.
- 18. (previously presented) The dosage form of Claim 1 that is a chewing gum.
- 19. (previously presented) The dosage form of Claim 1 that is a sublingual tablet.
- 20. (previously presented) The dosage form of Claim 1 that is a mucoadhesive film.
- 21. (previously presented) The dosage form of Claim 1 that is an oral strip.
- 22. (previously presented) The dosage form of Claim 1 that is an oral fast-melt tablet.
- 23. (previously presented) A pharmaceutical dosage form comprising (a) a therapeutically or sexual stimulatorily effective amount of about 0.1 mg to about 10 mg per dose of a therapeutic agent that comprises at least one compound of formula

$$X \xrightarrow{\prod_{D \in \mathcal{A}} R^3} R^3$$

or a pharmaceutically acceptable water-soluble salt thereof, said compound or salt thereof being water-soluble, wherein

 $R^1$ ,  $R^2$  and  $R^3$  are the same or different and are H,  $C_{1-6}$  alkyl (optionally phenyl substituted),  $C_{3-5}$  alkenyl or alkynyl or  $C_{3-10}$  cycloalkyl, or where

R3 is as above and R1 and R2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;

X is H, F, Cl, Br, I, OH, C<sub>1-6</sub> alkyl or alkoxy, CN, carboxamide, carboxyl or (C<sub>1-6</sub> alkyl)carbonyl;

A is CH, CH2, CHF, CHCI, CHBr, CHI, CHCH3, C=O, C=S, CSCH3, C=NH, CNH2, CNHCH3, CNHCOOCH3, CNHCN, SO2 or N;

> B is CH, CH2, CHF, CHCI, CHBr, CHI, C=O, N, NH or NCH3, and n is 0 or 1; and D is CH, CH2, CHF, CHCI, CHBr, CHI, C=O, O, N, NH or NCH3;

and (b) one or more pharmaceutically acceptable excipients; the dosage form being an oral dosage form selected from the group consisting of fast-melt formulations. breath-freshening pastilles, chewing gums, sublingual tablets, mucoadhesive films and oral strips, and having acceptable organoleptic properties.

- 24. (original) The dosage form of Claim 23 wherein the water-soluble compound or salt thereof has a solubility in water at 20-25°C of at least about 10 g/1.
- 25. (original) The dosage form of Claim 23 wherein the water-soluble compound or salt thereof is disclosed generically or specifically in U.S. Patent No. 5,273,975.

26-31. (cancelled)

- 32. (previously presented) The dosage form of Claim 23 that dissolves in the mouth without need for drinking water or other fluid.
- 33. (previously presented) The dosage form of Claim 23 that is a breath-freshening pastille.
- 34. (previously presented) The dosage form of Claim 23 that is a chewing gum.
- 35. (previously presented) The dosage form of Claim 23 that is a sublingual tablet.
- 36. (previously presented) The dosage form of Claim 23 that is a mucoadhesive film.
- 37. (previously presented) The dosage form of Claim 23 that is an oral strip.
- 38. (previously presented) The dosage form of Claim 23 that is an oral fast-melt tablet.
- 39. (withdrawn) A method of treating sexual dysfunction in a subject comprising intraoral administration of a dosage form of Claim 1 to the subject, less than about 1 hour prior to sexual activity.
- 40. (withdrawn) A method of treating sexual dysfunction in a subject comprising USERS\DOC\$\LA21952\LPAED\4s%d01!.DOC / 229041

intraoral administration of a dosage form of Claim 23 to the subject, less than about 1 hour prior to sexual activity.

- 41. (withdrawn) A method of enhancing sexual desire, interest or performance in a subject comprising intraoral administration of a dosage form of Claim 1 to the subject, less than about 1 hour prior to sexual activity.
- 42. (withdrawn) A method of enhancing sexual desire, interest or performance in a subject comprising intraoral administration of a dosage form of Claim 23 to the subject, less than about 1 hour prior to sexual activity.